The trading price of Second Sight Medical Products, Inc. (NASDAQ:EYES) floating higher at last check on Wednesday, Jan 13, closing at $1.63, 7.36% higher than its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Traders who pay close attention to intraday price movement should know that it has been fluctuating between $1.6200 and $1.8400. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 2.48. In examining the 52-week price action we see that the stock hit a 52-week high of $6.4 and a 52-week low of $0.69. Over the past month, the stock has gained 11.64% in value.

Analysts have forecast the company to bring in revenue of $240Million for the quarter, with the likely lows of $240Million and highs of $240Million. The average estimate suggests sales will likely down by -49.2% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $960Million. The company’s revenue is forecast to drop by -71.6% over what it did in 2020.

On the technical side, indicators suggest EYES has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned EYES a recommendation rating is 1. Out of them, no one rate it a Hold, while 1 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged Second Sight Medical Products, Inc. (EYES) as Underperform, while not any of them advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that EYEs price is currently -11.97% off the SMA20 and 24.45% off the SMA50. The RSI metric on the 14-day chart is currently showing 49.29, and weekly volatility stands at 15.67%. When measured over the past 30 days, the indicator reaches 19.52%. Second Sight Medical Products, Inc. (NASDAQ:EYES)’s beta value is currently sitting at 2.48, while the Average True Range indicator is currently displaying 0.34. With analysts defining $10-$10 as the low and high price targets, we arrive at a consensus price target of $10 for the trailing 12-month period. The current price is about 471.43% off the estimated low and 471.43% off the forecast high, based on this estimate. Investors will be thrilled if EYEs share price rises to $10, which is the median consensus price. At that level, EYEs share price would be +471.43% above current price.

To see how Second Sight Medical Products, Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: EYES stock’s performance was +7.36% at last check in today’s session, and -70.52% in the past year, while Thermo Fisher Scientific Inc (TMO) has been trading +1.14% in recent session and positioned +50.22% higher than it was a year ago. Another comparable company Intuitive Surg Inc (ISRG) saw its stock trading 4.15% higher in today’s session but was up +30.73% in a year. Furthermore, Edwards Lifesciences Corp (EW) showed an increase of 7.36% today while its price kept declining at -70.52% over the past year. Second Sight Medical Products, Inc. has a P/E ratio of 0, compared to Thermo Fisher Scientific Inc’s 40.87 and Intuitive Surg Inc’s 89.86. Also during today’s trading, the S&P 500 Index has surged 0.11%, while the Dow Jones Industrial also saw a negative seesion, down -0.1% today.

An evaluation of the daily trading volume of Second Sight Medical Products, Inc. (NASDAQ:EYES) indicates that the 3-month average is 2.2 Million. However, this figure has declined over the past 10 days to an average of 2.2 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently, records show that 23.21 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 43.09% of outstanding shares, whereas institutions hold 32.62%. The stats also highlight that short interest as of December 30, 2020, stood at 437.71 Million shares, resulting in a short ratio of 0.09 at that time. From this, we can conclude that short interest is 1.89% of the company’s total outstanding shares. It is noteworthy that short shares in December were up slightly from the previous month’s figure, which was 195.5 Million. However, since the stock’s price has seen -12.83% year-to-date, investors’ interest is likely to be reignited due to its potential to move higher ahead.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on..

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free


Please enter your comment!
Please enter your name here